Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study. Issue 14 (5th October 2021)

• Record Type: Journal Article
• Authors: Pereyra, David; Heber, Stefan; Schrottmaier, Waltraud C; Santol, Jonas; Pirabe, Anita; Schmuckenschlager, Anna; Kammerer, Kerstin; Ammon, Daphni; Sorz, Thomas; Fritsch, Fabian; Hayden, Hubert; Pawelka, Erich; Krüger, Philipp; Rumpf, Benedikt; Traugott, Marianna T; Glaser, Pia; Firbas, Christa; Schörgenhofer, Christian; Seitz, Tamara; Karolyi, Mario; Pabinger, Ingrid; Brostjan, Christine; Starlinger, Patrick; Weiss, Günter; Bellmann-Weiler, Rosa; Salzer, Helmut J F; Jilma, Bernd; Zoufaly, Alexander; Assinger, Alice
• Is Part Of: Cardiovascular research. Volume 117:Issue 14(2021)
• Page Start: 2807
• Page End: 2820
• Publication Date: 2021-10-05
• Subjects: COVID-19-associated coagulopathy -- Anticoagulation -- Low-molecular-weight heparin -- Thromboinflammation -- SARS-CoV-2 viral persistence; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Periodicals; 616.1
• DOI: 10.1093/cvr/cvab308
• Languages: English
• ISSNs: 0008-6363

Abstract

Abstract: Aims : Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence. Methods and results: Data of 586 hospitalized COVID-19 patients from three different regions of Austria were evaluated retrospectively. Of these, 419 (71.5%) patients received LMWH and 62 (10.5%) received non-vitamin-K oral anticoagulants (NOACs) during hospitalization. Plasma was collected at different time points in a subset of 106 patients in order to evaluate markers of thromboinflammation (H3Cit-DNA) and the cell death marker cell-free DNA (cfDNA). Use of LMWH was associated with improved survival upon multivariable Cox regression (hazard ratio = 0.561, 95% confidence interval: 0.348–0.906). Interestingly, neither LMWH nor NOAC was associated with attenuation of D-dimer increase over time, or thromboinflammation. In contrast, anticoagulation was associated with a decrease in cfDNA during hospitalization, and curtailed viral persistence was observed in patients using LMWH leading to a 4-day reduction of virus positivity upon quantitative polymerase chain reaction [13 (interquartile range: 6–24) vs. 9 (interquartile range: 5–16) days, P = 0.009]. Conclusion : Time courses of haemostatic and thromboinflammatory biomarkers were similar in patients with and without LMWH, indicating either no effects of LMWH on haemostasis or that LMWH reduced hypercoagulability to levels of patients without LMWH. Nonetheless, anticoagulation with LMWH was associated with reduced mortality, improved markers of cell death, and curtailed viral persistence, indicating potential beneficial effects of LMWH beyond haemostasis, which encourages use of LMWH in COVID-19 patients without contraindications. Graphical Abstract: